JPRN-UMIN000047062已完成Unknown
Prototype implementation test at Pharmalize Holding for social implementation of lunch box for improving Minor Health Complaints - Beneficial Effect of the Functional Lunch Boxes on Improving Minor Health Complaints
Medical Front Corporation0 个研究点目标入组 30 人开始时间: 2023年3月31日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Subjects who are under physicians advice, treatment, and/or medication for schizophreni a depression, mania, neurological disorders, and/or sleep disorders. 2. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 3. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 4. Subjects with implantable electronic medical devices. 5. Subjects who are under nutritional advice by a physician. 6. Pre- or post-menopausal women complaining of obvious physical changes. 7. Subjects who cannot continue to consume the test foods due to allergic reactions to drugs or foods (especially wheat and grass), and those who regularly use health foods including drugs and supplements that affect stress and sleep. 8. Subjects who regularly use medicines (sleeping pills, psychotropic drugs, etc.) or health foods/supplements (glycine, gamma-aminobutyric acid, L-serine, L-theanine, L-ornithine, reduced coenzyme Q10, etc.) that affect stress and sleep. 9. Heavy smokers, alcohol addicts or subjects with disordered lifestyle. 10. Subjects who donated either 400 ml whole blood within 16 wks (women), 12 wks (men), 200 ml whole blood within 4 wks, or blood components within 2 wks, prior to the current study. 11. Pregnant or lactating women or women who expect to be pregnant during this study. 12. Subjects who currently participate in other clinical trials or participated within the last 4 wks prior to the current study. 13. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.
研究者
相似试验
进行中（未招募）
不适用
An open-label phase I/II (proof of concept) trial of an combination of Nilotinib (AMN 107) and RAD001 in patients with acute myeloid leukemia - CAMN107ADE01EUCTR2007-000502-70-DETechnical University of Munich
尚未招募
不适用
Investigating the effect of a Rugby League Community program on Women's HealthDepressionAnxietyPhysical InactivityInsufficient dietary intakePublic Health - Health promotion/educationDiet and Nutrition - ObesityMental Health - DepressionObesityACTRN12621000966897Western Sydney University20
已完成
1 期
Phase I trial: Labcorp Drug Development Study: 8479217The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN14340698Bergenbio ASA6
已完成
1 期
Preclinical basic functionality testing of a new prototype lower limb exoskeleton during common locomotion tasksI61I63I69.4G82R54Intracerebral haemorrhageSequelae of stroke, not specified as haemorrhage or infarctionParaplegia and tetraplegiaSenilityCerebral infarctionDRKS00012374Zürcher Hochschule für Angewandte Wissenschaften20
招募中
不适用
Pilot study on the practicability of a prototype for measuring capillary refill timeMicrocirculation disorders after blood loss, volume shift or during single lung ventilationDRKS00023850Klinik & Poliklinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Carl Gustav Carus Dresden90